XML 36 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows-Indirect Method - BRL (R$)
R$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities      
Net income from continuing operations R$ 818,614 R$ 647,064 R$ 895,201
Adjustments to reconcile net income to cash provided by operating activities from continuing operations      
Share of loss (profit) of joint ventures and associates 17,634 44,031 12,708
Amortization of contractual assets with customers – exclusive rights 282,521 289,436 355,250
Amortization of right-of-use assets 260,716 242,670 216,609
Depreciation and amortization 653,118 595,531 551,768
PIS and COFINS credits on depreciation 7,081 6,062 4,891
Interest and foreign exchange rate variations 1,133,882 533,926 1,043,899
Deferred income and social contribution taxes (242,246) (234,244) 2,633
Current income and social contribution taxes 430,280 538,761 467,345
Loss on disposal of property, plant, and equipment and intangibles (184,189) (85,455) (1,700)
Reversion (loss) allowance for expected credit losses (3,123) 15,281 34,981
Provision for losses in inventories (826) 1,338 (115)
Provision for post-employment benefits (2,393) (15,867) 14,749
Equity instrument granted 9,364 8,793 6,222
Provision of decarbonization – CBIO 161,281 124,287 0
Provision for tax, civil, and labor risks 93,328 21,582 31,595
Other provisions and adjustments 2,332 (1,912) 5,829
Cash flows from operations before changes in working capital 3,437,374 2,731,284 3,641,865
(Increase) decrease in current assets      
Trade receivables and reseller financing (968,787) 481,984 240,474
Inventories (1,626,670) 108,136 (486,534)
Recoverable taxes (672,607) (115,316) (633,069)
Dividends received from joint ventures 1,005 4,836 4,108
Other receivables (24,360) (18,922) 24,335
Prepaid expenses (61,573) (70,503) (13,368)
Increase (decrease) in current liabilities      
Trade payables 2,425,821 798,180 77,131
Salaries and related charges 63,066 15,644 9,872
Taxes payable 11,733 22,925 (10,291)
Post-employment benefits (2,814) 1,273 (15,355)
Other payables (36,357) (16,663) 61,966
Deferred revenue (10,614) (9,814) 769
(Increase) decrease in non-current assets      
Trade receivables and reseller financing 12,008 (73,035) 11,333
Recoverable taxes (153,526) (667,894) (28,182)
Escrow deposits (43,324) (26,492) (35,064)
Other receivables 73,903 (27,738) (801)
Prepaid expenses 35,962 6,683 8,573
Increase (decrease) in non-current liabilities      
Post-employment benefits 11,907 8,700 (18,632)
Provision for tax, civil, and labor risks (28) (104) 0
Other payables (17,193) (34,721) 9,637
Deferred revenue 0 0 (11,850)
Acquisition of CBIO (176,837) (125,345) 0
Payments of contractual assets with customers – exclusive rights (420,261) (356,045) (330,068)
Payments of contingencies (24,351) (39,256) (22,966)
Income and social contribution taxes paid (230,036) (333,784) (111,499)
Net cash provided by operating activities from continuing operations 1,603,441 2,264,013 2,372,384
Net cash provided by operating activities from discontinued operations 982,519 874,106 552,468
Net cash provided by operating activities 2,585,960 3,138,119 2,924,852
Cash flows from investing activities      
Financial investments, net of redemptions 1,863,053 (869,748) 102,911
Acquisition of property, plant, and equipment (1,028,419) (750,618) (720,779)
Acquisition of intangible assets (237,488) (154,534) (111,251)
Revenue on disposal of investments 159,657 0 0
Capital increase in joint ventures (25,700) (28,840) (79,124)
Capital decrease in associates 1,500 0 0
Initial direct costs of right-of-use assets (14,905) 0 (68,007)
Related parties 2,334 0 0
Proceeds from disposal of property, plant, and equipment and intangibles 162,837 154,725 36,912
Net cash provided by (used in) investing activities from continuing operations 882,869 (1,649,015) (839,338)
Net cash provided by (used in) investing activities from discontinued operations (158,733) (487,390) (995,923)
Net cash provided by (used in) investing activities 724,136 (2,136,405) (1,835,261)
Loans and debentures      
Proceeds 1,383,611 3,387,161 2,009,221
Repayments (2,426,222) (1,815,130) (2,460,941)
Interest paid (733,791) (701,458) (1,416,977)
Payments of lease      
Principal (304,975) (250,202) (210,147)
Interest paid (15,267) (5,705) (11,892)
Dividends paid (705,753) (284,767) (596,436)
Capital increase from non-controlling shareholders 0 0 6,996
Related parties (177) (2,548) (146)
Net cash provided by (used in) in financing activities from continuing operations (2,802,574) 327,351 (2,680,322)
Net cash provided by (used in) in financing activities from discontinued operations (552,967) (919,684) (241,907)
Net cash provided by (used in) in financing activities (3,355,541) (592,333) (2,922,229)
Effect of exchange rate changes on cash and cash equivalents in foreign currency - continuing operations (4,547) 21,912 (21,805)
Effect of exchange rate changes on cash and cash equivalents in foreign currency - discontinued operations 56,553 114,822 30,871
Increase (decrease) in cash and cash equivalents 6,561 546,115 (1,823,572)
Cash and cash equivalents at the beginning of the year 2,661,494 2,115,379 3,938,951
Cash and cash equivalents at the end of the year 2,668,055 2,661,494 2,115,379
Cash and cash equivalents at the end of the year - continuing operations 2,280,074 0 0
Cash and cash equivalents at the end of the year - discontinued operations 387,981 0 0
Transactions without cash effect:      
Addition on right-of-use assets and leases payable 227,977 420,070 311,106
Addition on contractual assets with customers – exclusive rights 269,725 193,040 0
Reversion fund – private pension 2,656 33,843 0
Issuance of shares related to the subscription warrants – indemnification – Extrafarma acquisition R$ 1,819 R$ 54,763 R$ 0